Zydus Cadila gets USFDA nod to market alcohol abstinence drug
New Delhi: Drug firm Zydus Cadila has received approval from the US health regulator to market Acamprosate calcium delayed-release tablets used for maintenance of abstinence from alcohol in the US market.
"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Acamprosate calcium delayed-release tablets, 333 mg", Cadila Healthcare said in a BSE filing.
The drug will be produced at the groups formulations manufacturing facility at Baddi, it added.
"This medication is used for maintenance of abstinence from alcohol in patients with alcohol dependence", Cadila Healthcare said.
The group now has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process in financial year 2003 -04, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd